Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma

This study is testing a new type of immune cell therapy called CD5-targeted CAR-T cell therapy for people with a specific type of blood cancer called relapsed or refractory CD5-positive T-cell lymphoma. CAR-T therapy involves taking a patient's own immune cells, engineering them in a lab to attack cancer cells, then infusing them back. This approach targets a protein called CD5 found on these cancer cells. **You may be eligible if...** - You have been diagnosed with CD5-positive T-cell non-Hodgkin lymphoma (confirmed by biopsy) - Your cancer has come back or did not respond to at least two prior treatments, or relapsed after a stem cell transplant - More than 90% of your cancer cells express the CD5 protein - Your heart, liver, and kidney function meet minimum safety requirements - Your ECOG performance status is 0–2 (able to care for yourself) - You are willing to use contraception for at least 6 months after treatment **You may NOT be eligible if...** - You have epilepsy or a history of seizures - You have active hepatitis B, C, or E infection - You have uncontrolled active infections - You have previously received any gene therapy - You received certain other cancer treatments within the last few days or weeks - You have severe heart problems (irregular heart rhythm with prolonged QT interval) Talk to your doctor to see if this trial is right for you.